The Medical Research Council Myeloma IX trial: The impact on treatment paradigms

European Journal of Haematology

Volumn 88, Issue 1, 2012, Pages 1-7

  Richardson, Paul G ^a   Laubach, Jacob P ^a   Schlossman, Robert L ^a   Ghobrial, Irene M ^a   Mitsiades, Constantine S ^a   Rosenblatt, Jacalyn ^b   Mahindra, Anuj ^c   Raje, Noopur ^c   Munshi, Nikhil ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bisphosphonate; Clodronate; Multiple myeloma; Pamidronate; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CALCIUM; CLODRONIC ACID; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DICKKOPF 1 PROTEIN; HYDROXYUREA; I KAPPA B; IMATINIB; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; THALIDOMIDE; ZOLEDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; BONE DENSITY; BONE DISEASE; BONE MARROW BIOPSY; CALCIUM BLOOD LEVEL; CANCER INHIBITION; CELL ACTIVATION; CELL FATE; CYTOKINE RELEASE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FRAGILITY FRACTURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNITY; JAW OSTEONECROSIS; MORBIDITY; MULTIPLE MYELOMA; NONHUMAN; OSTEOLYSIS; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL; T LYMPHOCYTE ACTIVATION; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; CLODRONIC ACID; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; MULTIPLE MYELOMA; OSTEOLYSIS; PRACTICE GUIDELINES AS TOPIC;

EID: 83655201128     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01721.x     Document Type: Review

References (42)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
3. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009;84:1095-110.
4. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9.
5. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
6. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80:733-7.
7. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005;16:1223-31.
8. Bouvard B, Royer M, Chappard D, Audran M, Hoppe E, Legrand E. Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis. Joint Bone Spine 2010;77:120-4.
9. Edwards BJ, Langman CB, Bunta AD, Vicuna M, Favus M. Secondary contributors to bone loss in osteoporosis related hip fractures. Osteoporos Int 2008;19:991-9.
10. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-72.
11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. v.1.2012. Fort Washington, PA: National Comprehensive Cancer Network Inc., 2011.
12. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-72.
13. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009;374:324-39.
14. Green J, Clezardin P. The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol 2010;37(Suppl 1):S3-11.
15. Neville-Webbe HL, Gnant M, Coleman RE. Potential anticancer properties of bisphosphonates. Semin Oncol 2010;37(Suppl 1):S53-65.
16. Tassone P, Galea E, Forciniti S, Tagliaferri P, Venuta S. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int J Oncol 2002;21:867-73.
17. Ural AU, Yilmaz MI, Avcu F, Pekel A, Zerman M, Nevruz O, Sengul A, Yalcin A. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol 2003;78:443-9.
18. Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V, Tagliaferri P, Venuta S. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000;14:841-4.
19. Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B, Vanderkerken K. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003;18:482-92.
20. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-90.
21. Avcu F, Ural AU, Yilmaz MI, Ozcan A, Ide T, Kurt B, Yalcin A. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane. Eur J Haematol 2005;74:496-500.
22. Guenther A, Gordon S, Tiemann M, Burger R, Bakker F, Green JR, Baum W, Roelofs AJ, Rogers MJ, Gramatzki M. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010;126:239-46.
23. Segawa H, Kimura S, Kuroda J, et al. Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth. Br J Haematol 2005;130:558-60.
24. Kimura S, Kuroda J, Segawa H, Sato K, Nogawa M, Yuasa T, Ottmann OG, Maekawa T. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 2004;79:37-43.
25. Gordon S, Helfrich MH, Sati HI, Greaves M, Ralston SH, Culligan DJ, Soutar RL, Rogers MJ. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol 2002;119:475-83.
26. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-92.
27. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007;24:227-30.
28. Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid vs. observation in patients with asymptomatic myeloma. Cancer 2008;113:1588-95.
29. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989-99.
30. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001;113:1035-43.
31. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602.
32. Berenson J, Dimopoulos M, Chen Y-M. Improved survival in patients with multiple myeloma and high BALP levels treated with zoledronic acid compared with pamidronate: univariate and multivariate models of hazard ratios. 48th ASH Annual Meeting and Exposition; 2006 December 9-12; Orlando, FL. Abstract 3589.
33. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289-94.
34. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2010;3:CD003188.
35. Mhaskar R, Redzepovic J, Wheatley K, Clark O, Glasmacher A, Miladinovic B, Kumar A, Djulbegovic B. Comparative effectiveness of bisphoshonates in multiple myeloma [ASH abstract]. Blood 2010;116:3028.
36. Moschetta M, Di Pietro G, Ria R, et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer 2010;46:420-9.
37. Terpos E, Christoulas D, Kokkoris P, Anargyrou K, Gavriatopoulou M, Migkou M, Tsionos K, Dimopoulos MA. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol 2010;21:1561-2.
38. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009;20:1303-17.
39. Bird J, Owen R, d'Sa S, Snowden J, Pratt G, Littlewood T, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J. Guidelines on the Diagnosis and Management of Multiple Myeloma. London: British Committee for Standards in Haematology in conjunction with the UK Myeloma Forum [UKMF], 2010.
40. Reece D, Sebag M, White D, Song K. A Canadian perspective on the use of bisphosphonates in the clinical management of multiple myeloma. New Evidence in Oncology. Published March 2011. Available at: Accessed November 1, 2011.
41. Rajkumar SV. Zoledronic acid in myeloma: MRC Myeloma IX. Lancet 2010;376:1965-6.
42. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist 2007;12:664-89.